Scancell Holdings PLC

Scancell Holdings PLC

#06564638 Active
B2bPhysical ProductServices

Scancell is a clinical stage biopharmaceutical company dedicated to developing innovative immunotherapies that harness the body's immune system to combat cancer and infectious diseases. Their proprietary research focuses on creating novel vaccines and monoclonal antibodies targeting specific protein modifications.

Founded: 14/04/2008
Industries: Other research and experimental development on natural sciences and engineeringOther human health activities
Location: Oxford

Products

  • Avidimab® Antibody Enhancement Platform
  • Glymab® Monoclonal Antibodies
  • Immunobody® Vaccines
  • Moditope® Cancer Vaccines

Services

  • Immunotherapy Development
  • Monoclonal Antibody Production
  • Vaccine Development

Financial Snapshot

Last accounts made up to 30 April 2024
Next accounts due 31 October 2025 (5 months)
Cash in Bank £14.82m
↓ -26%
EBITDA -£17.3m
↓ 62%
Total Liabilities £6.39m
↓ -20%
Employees 61
↑ 20%

Directors

Role:
Chief Executive Officer
Appointed:
18/11/2024
Nationality:
New Zealander
Age:
63 years
Role:
Managing Director
Appointed:
09/07/2024
Nationality:
French
Age:
51 years
Role:
Chartered Accountant
Appointed:
14/03/2024
Nationality:
British
Age:
39 years
Role:
Company Director
Appointed:
01/02/2023
Nationality:
French
Age:
65 years
Role:
Financier
Appointed:
24/09/2020
Nationality:
British
Age:
62 years
Role:
Director
Appointed:
23/10/2019
Nationality:
British
Age:
73 years
Role:
Investor
Appointed:
18/06/2019
Nationality:
British
Age:
63 years
Role:
Scientist
Appointed:
16/04/2008
Nationality:
British
Age:
67 years

People with Significant Control

Jeremy Charles Green
Nature of Control:
Ownership Of Shares 25 To 50 Percent
Notified On:
02/11/2020
Nationality:
British
Apr 2024Apr 2023Apr 2022
Income Statement
Turnover
Export Revenue
Sales
Other Operating Income
Other Operating Items
Cost of Sales
Raw Materials & Consumables
Gross Profit
Admin Expenses
Other Operating Charges
Depreciation
R&D Expenses
Operating Profit
EBITDA
Financial Revenue
Financial Expenses
Financial Profit/Loss
Interest Paid
Extraordinary Revenue
Extraordinary Expenses
Net Extraordinary Items
Pre-Tax Profit
Tax
Profit After Tax
Retained Profit
Balance Sheet
Non-Current Assets
Intangible Assets
Tangible Fixed Assets
Other Non-Current Assets
Current Assets
Stock
Debtors
Cash in Hand
Other Current Assets
Called Up Share Capital
P&L Account Reserve
Shareholder Funds
Other Shareholder Funds
Provisions
Long Term Debt
Creditors (> 1 year)
Other Non-Current Liabilities
Short Term Debt
Creditors
Creditors (< 1 year)
Other Current Liabilities
Key Metrics
Net Assets
Net Current Assets
Total Assets Less Current Liabilities
Working Capital
Enterprise Value
Added Value
Cashflow Before D&A
Other Information
Staff Costs
Number of Employees
6 shareholders available
Shareholder 1
Shares:
Percentage:
Filing Date:
Shareholder 2
Shares:
Percentage:
Filing Date:
Shareholder 3
Shares:
Percentage:
Filing Date:

Charges

No charges registered

Properties

No property information available

17 issuances recorded

Total Amount Raised (Valid Issuances)

Shares Issued (Valid Issuances)

Date CLASS
Shares Issued:
Price Per Share:
Amount Raised:
Filing:
Date CLASS
Shares Issued:
Price Per Share:
Amount Raised:
Filing:

Grants

No grant information available

Group Structure

Government Council Contracts Beta

No council contracts found

Company Filings

17/04/2025 Officers

Change Person Director Company With Change Date

17/12/2024 Capital

Capital Allotment Shares

21/11/2024 Officers

Appoint Person Director Company With Name Date

03/11/2024 Resolution

Resolution

31/10/2024 Accounts

Accounts With Accounts Type Group

02/08/2024 Capital

Second Filing Capital Allotment Shares

24/07/2024 Officers

Appoint Person Director Company With Name Date